Strateos
Strateos automates chemistry, biology, and tissue analysis into closed-loop robotic labs that accelerate drug discovery programs. Through a combination of best-in-class robotics and control systems, advanced software for imaging and analytics, and remote cloud laboratories, they enable pharmaceutical partners to more rapidly and efficiently discover new drug candidates. Born of a merger between Transcriptic and 3Scan, Strateos combines the strengths of those companies to amplify their impact and accelerate drug discovery. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combined automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development. By expressing life science methods as data, infrastructure virtualization will become possible. "Science-as-a-Service" will power the next generation of discovery, driven by huge efficiencies of both time and money. Transcriptic was founded in 2012 to create a better way to get lab work done. Tired of spending endless hours at the bench pretending to be slow, error-prone robots, they set out to build a modern solution to the day-to-day process of wet lab biology. Drawing on deep computer science and electrical engineering backgrounds in addition to life science, Strateos was born: a meticulously optimized, technology-enabled remote lab. Using state-of-the-art automation and control technology, and an emphasis on user experience and usability, they are working on building a stark contrast to the long, complicated sales process, high prices, and slow turnarounds of traditional CROs. They are working hard to build a great company that can be a true partner for your lab for a long time, progressively enabling ever greater levels of productivity and efficiency. They are scientists building for scientists.
Strateos automates chemistry, biology, and tissue analysis into closed-loop robotic labs that accelerate drug discovery programs. Through a combination of best-in-class robotics and control systems, advanced software for imaging and analytics, and remote cloud laboratories, they enable pharmaceutical partners to more rapidly and efficiently discover new drug candidates. Born of a merger between Transcriptic and 3Scan, Strateos combines the strengths of those companies to amplify their impact and accelerate drug discovery. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combined automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development. By expressing life science methods as data, infrastructure virtualization will become possible. "Science-as-a-Service" will power the next generation of discovery, driven by huge efficiencies of both time and money. Transcriptic was founded in 2012 to create a better way to get lab work done. Tired of spending endless hours at the bench pretending to be slow, error-prone robots, they set out to build a modern solution to the day-to-day process of wet lab biology. Drawing on deep computer science and electrical engineering backgrounds in addition to life science, Strateos was born: a meticulously optimized, technology-enabled remote lab. Using state-of-the-art automation and control technology, and an emphasis on user experience and usability, they are working on building a stark contrast to the long, complicated sales process, high prices, and slow turnarounds of traditional CROs. They are working hard to build a great company that can be a true partner for your lab for a long time, progressively enabling ever greater levels of productivity and efficiency. They are scientists building for scientists.
Strateos has raised $56.1M across 1 round. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Strateos is featured in
Similar companies
ALZpath is a biotech organization that offers innovative diagnostic options for Alzheimer's disease.
Reme-D is a cutting-edge technology company that has patented technology, which is revolutionizing healthcare in areas with limited resources by providing cost-effective and efficient disease testing systems. This ensures that everyone has equal access to essential medical diagnostics.
Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.
Lyora Therapeutics develops genetic medicines for inherited retinal diseases that currently have no treatment.
Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics. The company is creating a pipeline of precision oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.
Kuehnle Agrosystems, Inc. specializes in biotech research and development of plant-based systems used for producing biologically active compounds. Originally known as Kuehnle Agrosystems Company, LLC, the company was established in 2007 and is located in Honolulu, Hawaii.
ETI have fostered a protected, novel clinical gadget that eliminates galectin-3 from human blood. The gadget eliminates both bound and free galectin-3 from the course, offering another treatment choice that is less obtrusive and has less aftereffects than different treatments. The single-use apheresis segment specifically eliminates Galectin-3 from the body. It contains an exclusive, profoundly powerful catching particle and is underlying an organization that medical clinics definitely know how to utilize.
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
Tenon Medical, a biotech firm specializing in enhancing surgical solutions for the SI joint, was established in 2012 in Morgan Hill, California.
Aptevo Therapeutics is a biotech company based in Seattle that focuses on developing new treatments for cancer and blood disorders. They use a special technology called ADAPTIR™ to improve outcomes for cancer patients. The company is known for its supportive work environment, culture of innovation, and unique platform technology. As a result, Aptevo has been able to attract talented individuals with experience in other leading biotech companies such as Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.